# Primo N. Lara

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/primo-n-lara/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,295 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 73 |
| i10-index | 300 |
| OpenAlex ID | https://openalex.org/A5075799959 |
| ORCID iD | https://orcid.org/0000-0001-9512-0002 |
| Works | 899 |

## Researcher papers

- [Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer](https://scholariq.org/papers/docetaxel-and-estramustine-compared-with-mitoxantrone-and-prednisone-for/)
- [Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer](https://scholariq.org/papers/genomic-hallmarks-and-structural-variation-in-metastatic-prostate-cancer/)
- [Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/kidney-cancer-version-3-2022-nccn-clinical-practice-guidelines-in-oncology/)
- [Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/circulating-tumor-cell-counts-are-prognostic-of-overall-survival-in-swog-s0421-a/)
- [Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/randomized-phase-iii-placebo-controlled-trial-of-carboplatin-and-paclitaxel-with/)
- [Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16](https://scholariq.org/papers/evaluation-of-prostate-specific-antigen-declines-for-surrogacy-in-patients/)
- [NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024](https://scholariq.org/papers/nccn-guidelines-insights-kidney-cancer-version-2-2024/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.